Eyenovia (NASDAQ:EYEN) Given “Hold” Rating at Brookline Capital Management

Brookline Capital Management reissued their hold rating on shares of Eyenovia (NASDAQ:EYEN) in a research report sent to investors on Friday,Benzinga reports.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research note on Wednesday, November 13th. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a report on Friday.

Eyenovia Stock Performance

Shares of NASDAQ:EYEN opened at $0.10 on Friday. Eyenovia has a 12 month low of $0.09 and a 12 month high of $2.57. The business has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.71. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27. The firm has a market capitalization of $6.53 million, a PE ratio of -0.14 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period last year, the firm earned ($0.18) EPS. As a group, research analysts forecast that Eyenovia will post -0.5 earnings per share for the current year.

Insider Buying and Selling at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe bought 50,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were purchased at an average price of $0.57 per share, with a total value of $28,500.00. Following the purchase, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. The trade was a 151.85 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 7.10% of the stock is currently owned by insiders.

Institutional Trading of Eyenovia

A number of institutional investors have recently made changes to their positions in EYEN. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eyenovia during the 2nd quarter valued at about $26,000. Ground Swell Capital LLC acquired a new stake in Eyenovia during the 2nd quarter worth about $27,000. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares during the period. Financial Management Network Inc. acquired a new stake in shares of Eyenovia during the 3rd quarter valued at $39,000. Finally, SkyView Investment Advisors LLC purchased a new position in Eyenovia in the second quarter valued at about $87,000. 25.84% of the stock is owned by institutional investors and hedge funds.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.